All In Biotech

NDA 205394 · Gensco

Rizafilm

Rizatriptan Benzoate · Oral

Last checked: Nov 19, 2026Latest source record: Feb 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Apr 14, 2023

Approved uses

2

Original approval plus efficacy supplements

Registered trials

14

11 Phase 3, 1 recruiting

FAERS reports

1,646

1,034 serious, 34 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 28, 2026.

RizaFilm™ is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age. Limitations of Use RizaFilm should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with RizaFilm, the diagnosis of migraine should be reconsidered before RizaFilm is administered to treat any subsequent attacks. RizaFilm is not indicated for the preventive treatment of migraine. Safety and effectiveness of RizaFilm have not been established for cluster headache. RizaFilm is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age (1) Limitations of Use : Use only after a clear diagnosis of migraine has been established (1) Not indicated for the preventive treatment of migraine (1) Not indicated for the treatment of cluster headache (1)

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • RIZAFILM · RIZATRIPTAN BENZOATE EQ 5MG BASE · FILM, ORAL · Prescription
  • RIZAFILM · RIZATRIPTAN BENZOATE EQ 10MG BASE · FILM, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Rizatriptan Benzoate" as an intervention, any sponsor and status, largest first.

All 14 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective420
  • headache259
  • off label use247
  • nausea239
  • migraine204
  • product use in unapproved indication178
  • drug intolerance175
  • hypersensitivity169
  • fatigue140
  • swelling face132
  • angioedema128
  • dysphonia128

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20044
20057
20063
200721
200831
200928
201015
201120
201215
201342
201436
201532
201665
201761
201896
2019131
2020113
2021118
2022159
2023152
2024166
2025189
2026142

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2 on PubMed

Sponsor: Gensco

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.